Edwards Lifesciences Corp (EW) Stock Up 3.1% and Still Undervalued -- GF Score: 95/100
On May 22, 2026, Edwards Lifesciences Corp (EW) shares rose 3.1% to a current price of $85.78. The stock has fluctuated between $72.30 and $87.89 over the past
EW - Edwards Lifesciences Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$97.08
DETAILS
HIGH:
$110.00
LOW:
$85.00
MEDIAN:
$95.00
CONSENSUS:
$97.08
UPSIDE:
13.17%
Stock News
Is EW Overvalued? DCF Says Worth $51
On May 13, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown varied price performance recently. The stock has ex
Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Is Edwards Lifesciences Corp (EW) a Bargain After 3.5% Drop? GF Value Says Undervalued
On May 11, 2026, Edwards Lifesciences Corp (EW) shares fell 3.5%, bringing the current price to $77.17. The stock has experienced a 52-week range of $72.30 to $
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.
Edwards Lifesciences Announces Appointment of CFO
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planni.
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissue
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospectiv.
Artisan Global Opportunities Fund Q1 2026 Portfolio Activity
During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox. In addition to Linde, Shopify and Amazon, we also added to Woodward and Spotify during the quarter. We ended our investment campaigns in Netflix, Snowflake and RELX during the quarter.
Is EW Overvalued? DCF Says Worth $53
On April 29, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown mixed price performance recently. Over the past w
Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences.
Head-To-Head Review: LENSAR (NASDAQ:LNSR) vs. Edwards Lifesciences (NYSE:EW)
LENSAR (NASDAQ: LNSR - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Volatility and Risk LENSAR has a beta of 0.99,
Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.
EW's Q1 Earnings Beat, Revenues Match, '26 View Up, Stock Climbs
Edwards Lifesciences beats on Q1 earnings, matches revenue estimates, lifts 2026 outlook as TAVR and TMTT growth accelerates; shares rise on stronger guidance and margin expansion.
Edwards Lifesciences Stock Surges On Heart Valve Devices Growth
Edwards Lifesciences Corp (NYSE:EW) shares are up on Friday as the company reported strong first-quarter results, highlighting growth in its transcatheter mitral and tricuspid therapies.
Edwards Lifesciences Corp (EW) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Raised Guidance Propel Optimism
Sales Growth: 12.7% year-over-year increase in Q1 2026.Total Sales: $1.65 billion in Q1 2026.TAVR Sales: $1.2 billion, 11% increase over the prior year.TMTT Sa
Edwards Lifesciences Corporation (EW) Q1 2026 Earnings Call Transcript
Edwards Lifesciences Corporation (EW) Q1 2026 Earnings Call Transcript
Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves
Edwards Lifesciences beat Wall Street first-quarter estimates on Thursday, driven by robust demand for its artificial valves used in complex cardiac procedures, sending its shares up over 4% in extended trading.
Heart-Valve Maker Edwards Lifesciences Pops On First-Quarter Beat
Edwards Lifesciences stock advanced late Thursday on better-than-expected first-quarter sales and earnings.
Edwards Lifesciences Reports First Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to.
Price Targets
Edwards Lifesciences price target raised to $110 from $104 at Barclays
$110.00
(was $84.15)
Barclays
Edwards Lifesciences price target raised to $90 from $89 at Truist
$90.00
(was $83.15)
Truist Financial
Edwards Lifesciences price target raised to $93 from $92 at Evercore ISI
$93.00
(was $83.12)
Vijay Kumar
·
Evercore ISI
Edwards Lifesciences price target raised to $100 from $98 at BTIG
$100.00
(was $79.72)
BTIG
Edwards Lifesciences price target lowered to $85 from $87 at Canaccord
$85.00
(was $79.72)
William Plovanic
·
Canaccord Genuity
Edwards Lifesciences price target lowered to $95 from $100 at Mizuho
$95.00
(was $77.28)
Mizuho Securities
Edwards Lifesciences price target lowered to $89 from $92 at Truist
$89.00
(was $76.85)
Richard Newitter
·
Truist Financial
Edwards Lifesciences price target lowered to $95 from $108 at Goldman Sachs
$95.00
(was $77.05)
David Roman
·
Goldman Sachs
Edwards Lifesciences price target raised to $100 from $98 at Piper Sandler
$100.00
(was $77.05)
Piper Sandler
Edwards Lifesciences price target lowered to $94 from $95 at UBS
$94.00
(was $81.62)
Danielle Antalffy
·
UBS
Edwards Lifesciences price target raised to $110 from $105 at Stifel
$110.00
(was $84.35)
Stifel Nicolaus
Edwards Lifesciences price target raised to $98 from $95 at Piper Sandler
$98.00
(was $84.35)
Piper Sandler
Edwards Lifesciences price target raised to $95 from $92 at UBS
$95.00
(was $83.58)
Danielle Antalffy
·
UBS
Edwards Lifesciences price target raised to $90 from $87 at Baird
$90.00
(was $83.69)
Robert W. Baird
Edwards Lifesciences price target raised to $104 from $103 at Barclays
$104.00
(was $85.13)
Barclays
Edwards Lifesciences price target raised to $108 from $104 at Goldman Sachs
$108.00
(was $84.58)
David Roman
·
Goldman Sachs
Edwards Lifesciences price target raised to $105 from $100 at Stifel
$105.00
(was $85.85)
Rick Wise
·
Stifel Nicolaus
Edwards Lifesciences price target raised to $94 from $92 at Evercore ISI
$94.00
(was $84.34)
Evercore ISI
JPMorgan Upgrades Edwards Lifesciences (EW) to Overweight
$100.00
(was $84.84)
Wells Fargo
Edwards Lifesciences price target lowered to $87 from $89 at Canaccord
$87.00
(was $85.32)
William Plovanic
·
Canaccord Genuity